Progyny is a healthcare company specializing in fertility benefits and services. Its core offerings include comprehensive fertility treatment coverage, personalized care, and access to a network of fertility specialists. The company primarily generates revenue through employer-sponsored fertility benefit plans, which cater to organizations seeking to support employees facing fertility challenges. Progyny's business segments focus on both direct-to-employer sales and partnerships with healthcare providers.
The investment profile of Progyny is more aligned with growth investors, given its focus on expanding fertility services and increasing employer partnerships. The company demonstrates potential for revenue growth, supported by a favorable market environment. However, it does not currently offer dividends, making it less suitable for income-focused investors.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-24 | Buy | Hold | Weak momentum and high risk offset potential growth. |
| 2026-08-29 | Hold | Buy | Mixed momentum; fundamentals show promise but uncertainty remains. |
| 2026-08-21 | — | Hold | Positive EPS growth, but recent negative momentum concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-08 | Jefferies | Target Raised | — → 33 | 25.94 |
| 2026-08-20 | Wells Fargo | Update | — → 37 | 25.53 |
| 2026-08-13 | Truist Financial | Target Raised | 33 → 36 | 25.74 |
| 2026-08-12 | Barclays | Target Lowered | 34 → 30 | 26.57 |
| 2026-08-07 | Canaccord Genuity | Target Lowered | 36 → 35 | 30.21 |
| 2026-07-28 | Barclays | Update | — → 34 | 31.59 |
| 2026-07-24 | BTIG | Target Raised | 30 → 40 | 30.7 |
| 2026-07-22 | Leerink Partners | Target Raised | 30 → 38 | 32.24 |
| 2026-07-21 | Canaccord Genuity | Target Raised | 30 → 36 | 31.77 |
| 2026-07-13 | KeyBanc | Target Raised | 30 → 35 | 30.65 |
| 2026-05-19 | Canaccord Genuity | Rating Upgraded | — → 30 | 24.05 |
